HtmlToText
drug development & delivery - the latest methods in drug development you are using an outdated browser. please upgrade your browser to improve your experience. submission guidelines about us back issues media planner contact free print subscription login -- -- subscriptions current/back issues market news & trends executive interviews -- select a section analytical/testing bioavailability & solubility bio platforms drug delivery devices excipients formulation development contract services sign up for a free subscription special feature – outsourcing formulation development & manufacturing: cdmos are innovating for 21st-century medicine contributor cindy h. dubin speaks with some of the industry’s leading cdmos about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof. contract services, featured articles, formulation development global report – 2017 global drug delivery & formulation report: part 4, the drug delivery & formulation pipeline in the final installment of this 4-part series, pharmacircle in collaboration with drug development & delivery, provides a pipeline review and analysis (centered on drug delivery and formulation products) looking forward and back 5 years for a total of 10 years. devices, drug delivery, featured articles, formulation development antibody discovery – why understanding immune dysregulation is the key to drug development david s. johnson, phd, provides a unique insight into immune dysregulation through a proprietary technology known as surge – a platform that quickly characterizes every cell in complex immune systems so that natural immune repertoires can be translated into medical treatments. bio platforms, bioavailability & solubility, drug delivery, featured articles, formulation development peptide delivery – the endometriosis enigma – why can’t there be a pill for that? joel tune, mba, says for those peptide therapeutics that meet the necessary criteria, advances in formulation technologies coupled with favorable market dynamics will continue to drive interest across the entire prescription drug spectrum for safe and effective orally administered peptide therapeutics. bio platforms, bioavailability & solubility, drug delivery, featured articles, formulation development microfluidics – taking a microfluidics approach to drug delivery richard gray, ma, and pavel abdulkin, phd, look at how microfluidics is changing the drug development sector and explore an exciting new non-encapsulating microparticle-based approach that offers “tunable” release of the api. drug delivery, featured articles, formulation development personalized immunotherapy – off-the-shelf personalized immunotherapy for breast cancer: the briacell solution william v. williams, md, markus lacher, phd, and charles l. wiseman, md, explain how there is a clear need for ways to stimulate effective cancer-specific immune responses while avoiding time-consuming and costly individualized manufacturing. bio platforms, bioavailability & solubility, drug delivery, featured articles, formulation development therapeutic focus – antisense drug shown to significantly reduce triglyceride levels in patients with severe hypertriglyceridemia ioanna gouni-berthold, md, provides results from a clinical study indicating antisense technology can result in significant reductions in triglyceride levels in patients with hypertriglyceridemia. bio platforms, bioavailability & solubility, featured articles, formulation development multiparticulate system – advances in lipid multiparticulate technologies for controlled release jaspreet arora, phd, samantha saville, and brett waybrant, phd, focus on a controlled-release lmp formulation to identify optimum annealing conditions and to better understand the annealing mechanism. bio platforms, bioavailability & solubility, drug delivery, excipients, formulation development view more articles exclusive online content 7/9/2018 integrated partnerships paired with innovative approaches are a key to success as we come to learn more about the human body, the dynamics of the industry must react accordingly. a primary example of this is the fact that the dominating blockbuster drug model that was paramount in the industry until a couple of years ago is no longer valid…… 7/8/2018 pfenex receives milestone from merck pfenex inc. recently announced the receipt of a milestone payment from merck associated with the initiation of the first phase 3 clinical study of (v114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. 7/8/2018 immatics enters strategic partnership with genmab immatics biotechnologies gmbh recently announced it has entered into a research collaboration and license agreement with genmab a/s to develop next-generation, t-cell engaging bispecific immunotherapies targeting multiple cancer indications. 7/8/2018 gerresheimer acquires sensile medical with the acquisition of sensile medical ag, switzerland under a recent share purchase agreement, gerresheimer is extending its business model in the direction of an original equipment manufacturer (oem) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers. 7/3/2018 biologic excipients market expected to be valued at $1.7 billion by end of 2028 future market insights (fmi) delivers key insights on the global biologic excipients market in its upcoming report titled biologic excipients market: global industry analysis 2013–2017 and opportunity assessment… 7/2/2018 lonza launches new bioscience website lonza bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com. 6/28/2018 evonik expands north american contract development & manufacturing capabilities for advanced injectables evonik recently announced a €35 million expansion of its contract development and manufacturing (cdmo) capabilities in north america to meet growing demand for controlled release… 6/21/2018 novacap to expand its pharmaceutical offering in us with major acquisition novacap recently announced it has signed an agreement to acquire boston-based pci synthesis, a leading us pharmaceutical contract development and manufacturing organization (cdmo), further reinforcing novacap’s capabilities and offering for the pharmaceutical industry. 6/21/2018 epinephrine nasal spray in development for treatment of anaphylaxis shows promise as potential alternative to intramuscular injection insys therapeutics, inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that its investigational epinephrine nasal spray showed promise in an early clinical trial as a potential needle-free, non-invasive and easy-to-use alternative to intramuscular injection for the treatment of anaphylaxis. 6/13/2018 pfanstiehl launched new cgmp-produced galactose for cell culture media optimization & production of therapeutic recombinant glycoproteins as part of pfanstiehl’s continual commitment to producing the industry’s highest purity, lowest endotoxin and lowest metals (hple-lm) for bioprocessing components, two new d-galactose products have been launched. view more exclusive online content market news & trends 7/12/2018 translate bio announces closing of collaboration & licensing agreement with sanofi pasteur 7/12/2018 wuxi biologics & immune pharmaceuticals announce late-phase development & manufacturing partnership 7/12/2018 fda grants fast-track designation to aclaris therapeutics’ investigational jak inhibitor 7/12/2018 hemispherx files positive safety report on intranasal use of ampligen in combination with flumist influenza vaccine 7/12/2018 aurin biotech awarded us patent for cancer drug 7/12/2018 catalent biologics adopts berkeley lights’ beacon
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: DRUG-DEV.COM
Registry Domain ID: 1626992381_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.networksolutions.com
Registrar URL: http://networksolutions.com
Updated Date: 2015-09-24T15:10:53Z
Creation Date: 2010-11-23T20:54:33Z
Registry Expiry Date: 2020-11-23T20:54:33Z
Registrar: Network Solutions, LLC.
Registrar IANA ID: 2
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS.RACKSPACE.COM
Name Server: NS2.RACKSPACE.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-11-27T02:05:37Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Network Solutions, LLC.
SERVERS
SERVER com.whois-servers.net
ARGS domain =drug-dev.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME drug-dev.com
CHANGED 2015-09-24
CREATED 2010-11-23
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
NS.RACKSPACE.COM 69.20.95.4
NS2.RACKSPACE.COM 65.61.188.4
REGISTERED yes
Go to top
drug-dev.com rapport :
Visitez le site